{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:11Z","timestamp":1787181911041,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119746","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:46:22Z","timestamp":1784641582000},"page":"119746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting PNPLA3 I148M variant in MASLD: Cell-type specific mechanisms and precision therapy opportunities"],"prefix":"10.1016","volume":"202","author":[{"given":"Huainan","family":"Bu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1395-2014","authenticated-orcid":false,"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119746_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119746_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2026.119746_bib4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119746_bib5","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119746_bib6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jhep.2008.11.017","article-title":"Influence of ethnicity on histological differences in non-alcoholic fatty liver disease","volume":"50","author":"Mohanty","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2016.0109","article-title":"Genetic predisposition in nonalcoholic fatty liver disease","volume":"23","author":"Sookoian","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib8","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2026.119746_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.102495","article-title":"Global Epidemiology and Implications of PNPLA3 I148M Variant in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis","volume":"15","author":"Souza","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16123","article-title":"Global Epidemiological Impact of PNPLA3 I148M on Liver Disease","volume":"45","author":"Kozlitina","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2026.119746_bib11","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119746_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14728222.2021.2018418","article-title":"PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date","volume":"25","author":"Cherubini","year":"2021","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.biopha.2026.119746_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16133","article-title":"Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD","volume":"45","author":"Petta","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2026.119746_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16117","article-title":"Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk","volume":"45","author":"Castanho Martins","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2026.119746_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16186","article-title":"Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis","volume":"45","author":"Linden","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2026.119746_bib17","first-page":"75","article-title":"The PNPLA family of enzymes: characterisation and biological role","volume":"74","author":"Lulic","year":"2023","journal-title":"Arh. Hig. Rada Toksikol."},{"key":"10.1016\/j.biopha.2026.119746_bib18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/liv.14402","article-title":"Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH","volume":"40","author":"Bruschi","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2026.119746_bib19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbrc.2010.10.106","article-title":"Regulation of the promoter region of the human adiponutrin\/PNPLA3 gene by glucose and insulin","volume":"402","author":"Rae-Whitcombe","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119746_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2010.10.024","article-title":"Distinct regulation of adiponutrin\/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes","volume":"55","author":"Dubuquoy","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib21","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1073\/pnas.1003585107","article-title":"A feed-forward loop amplifies nutritional regulation of PNPLA3","volume":"107","author":"Huang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119746_bib22","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","article-title":"Interaction between estrogen receptor-alpha and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women","volume":"29","author":"Cherubini","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119746_bib23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s42255-019-0066-3","article-title":"Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes","volume":"1","author":"Yang","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.biopha.2026.119746_bib24","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1038\/s41467-024-49224-x","article-title":"PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein","volume":"15","author":"Johnson","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119746_bib25","doi-asserted-by":"crossref","first-page":"37085","DOI":"10.1074\/jbc.M111.290114","article-title":"Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease","volume":"286","author":"Huang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119746_bib26","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1074\/jbc.RA118.002333","article-title":"Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets","volume":"293","author":"Mitsche","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119746_bib27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hep.29273","article-title":"The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation","volume":"66","author":"BasuRay","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119746_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.27242","article-title":"Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis","volume":"61","author":"Smagris","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119746_bib29","doi-asserted-by":"crossref","first-page":"E1568","DOI":"10.1210\/jc.2015-2978","article-title":"The Genetic Variant I148M in PNPLA3 Is Associated With Increased Hepatic Retinyl-Palmitate Storage in Humans","volume":"100","author":"Kovarova","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2026.119746_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119746_bib31","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1074\/jbc.M109.064501","article-title":"A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis","volume":"285","author":"He","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119746_bib32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.bbalip.2013.12.006","article-title":"Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function","volume":"1841","author":"Pingitore","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2026.119746_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108186","article-title":"Lipid droplet targeting of the lipase coactivator ABHD5 and the fatty liver disease-causing variant PNPLA3 I148M is required to promote liver steatosis","volume":"301","author":"Teskey","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119746_bib34","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/hep.30583","article-title":"PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119746_bib35","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00125-014-3310-0","article-title":"PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans","volume":"57","author":"Peter","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2026.119746_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127902","article-title":"Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids","volume":"4","author":"Luukkonen","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2026.119746_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116371","article-title":"PNPLA3-I148M is a neomorph that interferes with two primary hepatic triglyceride clearance pathways","volume":"44","author":"Sherman","year":"2025","journal-title":"Cell. Rep."},{"key":"10.1016\/j.biopha.2026.119746_bib38","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2312291121","article-title":"The ubiquitin E3 ligase BFAR promotes degradation of PNPLA3","volume":"121","author":"Das","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119746_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112384","article-title":"Identification of NUV-244 as a PNPLA3 I148M degrading small molecule","volume":"28","author":"Steigemann","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.biopha.2026.119746_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.193805","article-title":"PNPLA3-I148M genetic variant rewires lipid metabolism to drive programmed cell death in human hepatocytes","volume":"10","author":"Florentino","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2026.119746_bib41","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cmet.2023.10.008","article-title":"The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans","volume":"35","author":"Luukkonen","year":"2023","journal-title":"Cell. Metab."},{"key":"10.1016\/j.biopha.2026.119746_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27031601","article-title":"The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones","volume":"27","author":"Paolini","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119746_bib43","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2010.01.003","article-title":"Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis","volume":"52","author":"Akazawa","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib44","doi-asserted-by":"crossref","first-page":"G236","DOI":"10.1152\/ajpgi.00091.2010","article-title":"CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis","volume":"299","author":"Cazanave","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.biopha.2026.119746_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/2872408","article-title":"PNPLA3 148M\/M Is More Susceptible to Palmitic Acid-Induced Endoplasmic Reticulum Stress-Associated Apoptosis in HepG2 Cells","volume":"2023","author":"Chen","year":"2023","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.biopha.2026.119746_bib46","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.29041","article-title":"The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells","volume":"65","author":"Bruschi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119746_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119681","article-title":"PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction","volume":"24","author":"Gou","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119746_bib48","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/hep4.1395","article-title":"PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells","volume":"3","author":"Bruschi","year":"2019","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.biopha.2026.119746_bib49","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1093\/hmg\/ddu121","article-title":"PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells","volume":"23","author":"Pirazzi","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2026.119746_bib50","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3945\/jn.115.210633","article-title":"PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity","volume":"145","author":"Mondul","year":"2015","journal-title":"J. Nutr."},{"key":"10.1016\/j.biopha.2026.119746_bib51","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jhep.2024.01.032","article-title":"Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models","volume":"80","author":"Caon","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228711","article-title":"PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells","volume":"21","author":"Bruschi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119746_bib53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2022.08.022","article-title":"IL-6\/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease","volume":"78","author":"Park","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep4.1450","article-title":"A Microphysiological System for Studying Nonalcoholic Steatohepatitis","volume":"4","author":"Kostrzewski","year":"2020","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.biopha.2026.119746_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040964","article-title":"Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis","volume":"9","author":"Hurrell","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119746_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2026.101380","article-title":"Nutrigenomics of fat-soluble vitamins and micronutrients in hepatocyte lipotoxicity and MASLD","volume":"101","author":"Migni","year":"2026","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.biopha.2026.119746_bib57","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.31609","article-title":"Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis","volume":"73","author":"Banini","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119746_bib58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Linden","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2026.119746_bib59","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119746_bib60","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2024.10.048","article-title":"PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis","volume":"82","author":"Wang","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116512","article-title":"GPX4, ferroptosis, and diseases","volume":"174","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119746_bib62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials","volume":"83","author":"Armisen","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119746_bib63","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:53:37Z","timestamp":1787180017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"alternative-id":["S0753332226007821"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119746","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PNPLA3 I148M variant in MASLD: Cell-type specific mechanisms and precision therapy opportunities","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119746"}}